Alize reports Phase II Prader-Willi data

Alize Pharma S.A.S. (Lyon, France) said once-daily subcutaneous AZP-531 for two weeks led to significant improvements in hyperphagia-related behavior vs. placebo

Read the full 218 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE